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ABSTRACT
Introduction: Patients with diabetic macular
edema (DME), a chronic, vision-limiting
condition, may be insufficiently responsive to
standard-of-care anti-vascular endothelial
growth factor (VEGF) and/or laser therapies.
One approved treatment for such patients is
0.2 lg/day fluocinolone acetonide (FAc)
sustained-release implant; however, data are
limited for treatment strategies in patients
with bilateral chronic DME insufficiently
responsive to standard-of-care therapies.
Methods: Six pseudophakic patients with
bilateral, chronic DME previously treated with
laser and anti-VEGF therapy (and intravitreal
triamcinolone acetonide in 10 eyes) were
retrospectively investigated for visual and
anatomical outcomes, 6 months
post-0.2 lg/day FAc implant in both eyes.
Results: At baseline, the mean best corrected
visual acuity (BCVA) was approximately 6/38 or
43 [standard deviation (SD) ±17.4] Early
Treatment Diabetic Retinopathy Study (ETDRS)
letters; mean central retinal thickness (CRT) was
648 lm (SD ±160). Mean change in BCVA was
?10 letters (SD ±12.2 letters), with 4/12 eyes
maintaining or achieving driving vision
(C70 letters) and 3/12 eyes having unchanged
BCVA. CRT was reduced 6 months after
0.2 lg/day FAc implant in 11/12 eyes. The
mean intraocular pressure (IOP) was
16.1 mmHg [mean change of 1.1 mmHg (SD
±3.6)].
Conclusion: In a real-world setting, 0.2 lg/day
FAc implant in both eyes was a feasible,
effective choice for patients with severe
bilateral DME, without notable increases in IOP.
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INTRODUCTION
Diabetic retinopathy (DR) is a visual
complication that presents in around 35% of
patients with diabetes [1]. A further visual
complication manifesting in 6.8% of patients
with DR is diabetic macular edema (DME), a
chronic condition that results in significant
reduction in vision and blindness in the
working-age population [1]. DME can be
unilateral or bilateral, with bilateral DME
presenting in approximately 33–46% of
patients with DME [2, 3]. Due to its chronic
nature and persistence, DME can be difficult to
manage, and without treatment nearly half of
all patients who develop DME will lose two or
more lines of visual acuity (VA) within 2 years
[4, 5].
Historically, the standard of care for DME
was laser therapy; however, vision gain
following such treatment was limited [6]. More
recently, several prospective randomized
clinical trials have shown significant gains in
VA in patients with DME following treatment
with anti-vascular endothelial growth factor
(VEGF) agents, resulting in a shift toward
anti-VEGF treatment as the preferred standard
of care and first line of treatment [6–9]. Despite
promising efficacy, however, results from the
RIDE (ClinicalTrials.gov identifier,
NCT00473382) and RISE (ClinicalTrials.gov
identifier, NCT00473330) trials investigating
the anti-VEGF agent, ranibizumab, found that
patients who crossed over from sham to
ranibizumab at 24 months were notably less
responsive to treatment. These data are
indicative of a subgroup of patients with
longer-term chronic DME who may be
insufficiently responsive to intermittent
therapies such as the injection of anti-VEGF
[8, 9].
Chronic DME is thought to be associated
with a more inflammatory state following a
shift in the expression of numerous
inflammatory cytokines and
VEGF-independent pathways responsible for
its pathogenesis [10]. Consequently, chronic
DME may require broader spectrum treatments
such as corticosteroids, which have
anti-inflammatory and angiostatic effects
[11–13].
ILUVIEN (Alimera Sciences Limited,
Aldershot, UK) is an intraocular,
nonbioerodible 0.2 lg/day fluocinolone
acetonide (FAc) sustained-release implant that
is approved in Europe for treatment of vision
impairment associated with chronic DME
considered insufficiently responsive to
available therapies [14]. The Fluocinolone
Acetonide in Diabetic Macular Edema (FAME;
ClinicalTrials.gov identifier, NCT00344968)
study compared 0.2 lg/day (the ultimately
approved dosage) FAc with sham injections in
patients with DME who were insufficiently
responsive to the standard of care at that time,
having received C1 focal laser treatment [15].
Three-year treatment with 0.2 lg/day FAc
implant was associated with a significant
improvement in vision outcomes, with the
greatest benefit being reported in patients with
chronic DME where 34.0% of patients treated
with 0.2 lg/day FAc implant gained C15 in
letter score at month 36 compared with only
13.4% of sham-treated patients [16]. However,
the FAc implant was associated with increased
intraocular pressure (IOP) compared with
sham-treated patients and increased risk of
cataract in patients who were phakic at
baseline. As such, in the UK, National Institute
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for Care and Health Excellence (NICE)
technology appraisal TA 301 recommends
0.2 lg/day FAc implant for pseudophakic
patients with chronic DME that are deemed by
the clinician to be insufficiently responsive to
laser or anti-VEGF.
Little published data exist for treatment
strategies in patients with bilateral chronic
DME who are deemed insufficiently responsive
to other therapies. Based on the NICE TA301
guidance, the 0.2 lg/day FAc implant in both
eyes could be a sensible consideration for these
patients in the UK setting. The summary of
product characteristics for 0.2 lg/day FAc
implant states that ‘Administration in both
eyes concurrently is not recommended’.
Nevertheless, concurrent use, with both eyes
injected at different time points, is not
contraindicated [14]. Moreover,
pharmacokinetic data over 36 months
demonstrated negligible systemic exposure to
FAc following treatment with 0.2 lg/day FAc
implant, highlighting its localized nature [14],
which would suggest concurrent treatment
would not present an unexpected side effect
profile. This retrospective study investigates
visual function, anatomical outcomes and
safety of 0.2 lg/day FAc implant in both eyes
of six patients with bilateral chronic DME.
METHODS
This retrospective case series analysis assessed
the visual function and anatomical measures at
baseline and after a 6-month follow-up in six
patients who received bilateral 0.2 lg/day FAc
implants between April 2014 and October 2014.
As a retrospective analysis, data were collected
using case notes and optical coherence
tomography (OCT) scans collected during
treatment as part of the standard care
pathway. Consequently, institutional review
board policies did not necessitate additional
ethics committee approval for this analysis.
Baseline demographics were collected from
patient records at the time of 0.2 lg/day FAc
implant and included age, gender, general
health, and disease and treatment history. In
addition, Snellen VA (at 6 m) and anatomical
measures using optical coherence tomography
[e.g., central retinal thickness (CRT), central
subfield foveal thickness (CSFT)] were noted at
baseline. Snellen VA was converted into
approximate Early Treatment Diabetic
Retinopathy Study (ETDRS) letters to facilitate
interpretation using the following equation:
85 ? 50 9 log (Snellen fraction), as described
by Gregori et al [17].
Efficacy assessments at 6-month follow-up
included changes in VA, anatomical measures
(including CRT and CSFT), and in the number
of fields out of 9 over 300 lm thickness. In
addition, safety was evaluated through




Overall, six patients with bilateral chronic DME
received 0.2 lg/day FAc implant in both eyes
(12 eyes). Baseline values and patient
demographics are summarized in Table 1. The
average patient age was 62.5 years (range
44–82); four patients had type-II diabetes and
two patients type-I diabetes. All patients were
pseudophakic at baseline, with one patient
having received unilateral vitrectomy (eye 9).
Five of six patients had bilateral subretinal fluid
(SRF), and four of six had bilateral epiretinal
membrane (ERM); the remaining patient(s) had
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unilateral SRF/ERM. Neovascularization of the
disc or of the retina outside of the disc was not
reported for any patients. At baseline, two
patients were receiving drops for bilateral IOP
(patients 2 and 3, Table 1).
Baseline BCVA ranged from 20 to 70 letters
(6/120–6/12), with a mean baseline BCVA in all
eyes of 43 letters (SD ±17.4; 6/38). At baseline,
only one eye (eye 10) had CRT B300 lm,
indicative of a dry macular. Mean baseline
CRT and CSFT values in all eyes were 648 lm
(SD ±160) and 637 lm (SD ±140), respectively,
and all eyes had C6 of 9 fields over 300 lm.
Baseline values were generally similar in fellow
eyes for each patient (Figs. 1, 2, 3, 4). All 12 eyes
had received both prior macular laser (C1 laser
therapy) and anti-VEGF (C3 intravitreal
injections of ranibizumab) treatment, with 10
eyes having also received prior intravitreal
triamcinolone (IVTA; C1 intravitreal injection)
for DME. In the patients studied, prior IVTA was
manageable with aqueous suppressants. The

















FAc implantLaser RBZ IVTA
1 Male 70 II 1 LE N 1 9 grid 99 19 July 29, 2014
2 RE N 1 9 grid 99 19 September 9,
2014
2 Female 58 II 3 RE Lumigan/Azarga 1 9 Focal 199 19 June 10,
2014
4 LE Lumigan/Azarga 2 9 Focal 199 19 September
23, 2014
3 Male 44 I 5 RE Latanoprost/timolol 1 9 grid 69 39 July 25, 2014
6 LE Latanoprost/timolol 1 9 grid 69 29 October 30,
2014
4 Male 82 II 7 RE N 1 9 grid 39 29 April 10,
2014
8 LE N 1 9 grid 39 19 July 11, 2014
5 Male 63 I 9 LE N 1 9 grid 69 0 July 18, 2014
10 RE N 1 9 grid 99 0 October 21,
2014
6 Female 58 II 11 RE N 1 9 grid 199 19 June 10,
2014
12 LE N 1 9 grid 199 19 September
23, 2014
DME diabetic macular edema, FAc ﬂuocinolone acetonide, IOP intraocular pressure, IVTA intravitreal triamcinolone, LE
left eye, RE right eye, RBZ ranibizumab
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history of prior treatment for DME is shown for
each eye in Table 1. All patients received
bilateral 0.2 lg/day FAc implant, with
2–3 months between injection of the implant
into the first and second eyes.
Six months following 0.2 lg/day FAc
implant, the mean change in BCVA for all
patients was ?10 letters (SD ±12.2; range -9 to
?35 letters). A gain of[10 letters from baseline
was reported in 7 of 12 (58.3%) eyes (Fig. 1),
with 5 of 12 (41.7%) eyes gaining C15 letters
from baseline and 4 (33.3%) eyes maintaining
or achieving driving vision of 70 letters. BCVA
remained unchanged 6 months post-0.2 lg/day
FAc implant in three eyes (25.0%), with only
one eye (8.3%) showing a worsening from
baseline (by -9 letters); however, the latter eye
showed the greatest reported reduction in CRT
(-660 lm from 830 lm). Overall, the trend of
VA response was not consistent, and an
improvement in one eye did not appear to
predict a corresponding improvement in the
fellow eye for four of six patients (66.7%;
patients 2, 3, 5, and 6). Patients 1 and 4
showed the best improvements of ?35 (eye 1)
and ?26 (eye 6) letters, respectively, in one eye
with a slightly smaller, but still notable,
improvement of ?15 letters in the fellow eye
(eyes 2 and 7) of both patients.
Six months post-0.2 lg/day FAc implant,
CRT was reduced in 11 (91.7%) eyes, and CSFT
was reduced in all eyes, with mean reductions of
-296.9 lm (SD ±219.7; range -660 to ?61 lm)
and -267.7 lm (SD ±186.4; range -574 to
-7 lm), respectively (Figs. 2, 3). Both CRT and
CSFT were reduced by C200 lm in seven
(58.3%) eyes, and the fellow eyes of individual
Fig. 1 Changes in BCVA before and 6 months after
0.2 lg/day FAc implant. Baseline BCVA and BCVA
6 months post-0.2 lg/day FAc implant is shown for each
eye. Eyes from the same patient are shown in the same
color, one with a solid line and the fellow eye with a dotted
line (patient 1 red; patient 2 yellow; patient 3 green; patient
4 gray; patient 5 blue; patient 6 purple). The change from
baseline is presented numerically for each eye and overall
(mean ± SD) in tabular format below the graph. BCVA
best corrected visual acuity, ETDRS Early Treatment
Diabetic Retinopathy Study, FAc ﬂuocinolone acetonide,
SD standard deviation
Fig. 2 Changes in CRT before and 6 months after
0.2 lg/day FAc implant. Baseline CRT (lm) and CRT
6 months post-0.2 lg/day FAc implant are shown for each
eye. Eyes from the same patient are shown in the same
color, one with a solid line and the fellow eye with a dotted
line (patient 1 red; patient 2 yellow; patient 3 green; patient
4 gray; patient 5 blue; patient 6 purple). The change from
baseline is presented numerically for each eye, and overall
(mean ± SD) in tabular format below the graph. CRT
central retinal thickness, FAc ﬂuocinolone acetonide, SD
standard deviation
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patients appeared to be mostly comparable. The
number of fields out of 9 over 300 lm was also
reduced in 8 of 12 (66.7%) eyes.
Two eyes (eyes 1 and 6, patients 1 and 3) that
achieved driving vision of 70 letters following
0.2 lg/day FAc implant showed
correspondingly large reductions in CRT of
-507 and -542 lm (from 777 and 730 lm),
respectively. Patient 5 (eyes 9 and 10) showed
no notable change in CRT from baseline in
either eye; however, both eyes showed relatively
low baseline CRT values in comparison to the
other eyes included in this study (403 and
269 lm). In addition, baseline BCVA was 70
letters in both eyes, and driving vision was
maintained following 0.2 lg/day FAc implant.
Patient 5 was also the only one who had not
received prior IVTA treatment; all other patients
had received bilateral IVTA. Patient 5 received
rescue ranibizumab treatment 5 months
post-0.2 lm/day FAc implant.
Mean baseline IOP was 14.6 mmHg (SD ±3.8,
range 10–20). Six months post-0.2 lg/day FAc
implant, mean IOP was 16.1 mmHg (SD ±3.8,
range 10–21), a mean change of 1.1 mmHg (SD
±3.6, range -4 to ?9). Patients 3 and 4
continued on bilateral IOP-lowering eyedrops,
with no other patients initiating IOP-lowering
treatment following 0.2 lg/day FAc implant. No
other treatment-related complications were
reported.
DISCUSSION
This study evaluated the bilateral injection of
0.2 lg/day FAc implant in six patients with
DME in both eyes in the real-world setting. All
eyes had received C1 macular laser treatment
and C3 ranibizumab injections and were
deemed insufficiently responsive to these
treatments. Ten eyes had also received C1
IVTA injection prior to 0.2 lg/day FAc
implant. The average CRT at baseline was high
(648 lm) and most eyes (10/12) had baseline
BCVA below 70 letters (6/12), the minimum
requirement for maintaining a driving license
in Europe [18]. Six months post-0.2 lg/day FAc
implant, 58.3% of eyes had gained[10 letters
and 41.7% C15 letters. Although the patient
numbers are small, these values are consistent
with outcomes reported in the FAME studies,
where 51.7% of eyes treated with 0.2 lg/day FAc
Fig. 3 Changes in CSFT before and 6 months after
0.2 lg/day FAc implant. Baseline CSFT (lm) and CSFT
6 months post-0.2 lg/day FAc implant are shown for each
eye. Eyes from the same patient are shown in the same
color, one with a solid line and the fellow eye with a dotted
line (patient 1 red; patient 2 yellow; patient 3 green; patient
4 gray; patient 5 blue; patient 6 purple). The change from
baseline is presented numerically for each eye, and overall
(mean ± SD) in tabular format below the graph. CSFT
central subﬁeld foveal thickness, FAc ﬂuocinolone ace-
tonide, SD standard deviation
Fig. 4 OCT images pre- and post-0.2 lg/day FAc implant
in eyes 1, 6, 9, and 10. The OCT images pre- and
post-0.2 lg/day FAc implant are shown for eyes 1, 6, 9,
and 10. Large reductions in CRT from following
0.2 lg/day FAc implant are shown for eyes 1 and 6; eyes
9 and 10 show less of a reduction. CRT central retinal
thickness, FAc ﬂuocinolone acetonide, OCT optical
coherence tomography, SD standard deviation
c
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implant gained[10 letters [19] and 34% gained
C15 letters [16]. Four patients had achieved or
maintained driving vision and there was a
notable reduction in CRT in all eyes with a
baseline CRT [600 lm. This is an important
outcome in the management of DME
progression, as prolonged edema results in
irreversible damage and permanent vision loss,
emphasizing the need for early intervention
[20]. Further, minimal increases in IOP were
observed and no patients needed to initiate
IOP-lowering medication post-0.2 lg/day FAc
implant.
Of the six patients who received bilateral
0.2 lg/day FAc implant in this study, five had
severe edema with CRT[600 lm in both eyes,
in addition to low VA below driving vision
after multiple prior treatments with macular
laser, ranibizumab, and IVTA. Further, all eyes
had foveal eversion on OCT. Taken together,
these data suggest that, in a real-world setting,
clinicians selected patients with severe
bilateral DME for 0.2 lg/day FAc implant in
both eyes. It is accepted that early
intervention and management of DME is
important in minimizing vision loss and
maintaining the quality of life in patients
with DME; this is perhaps even more
important when both eyes are affected,
increasing the risk of legal blindness. Further
sub-analyses of the RISE and RIDE trials with
ranibizumab found that patients with chronic
DME may become refractory to anti-VEGF
therapy once DME disease progresses [9]. If,
as some evidence suggests [10], this is
associated with a more complex
inflammatory cytokine state, treatment with
corticosteroids may be appropriate at an
earlier stage in patients with chronic DME.
In the FAME trials, the sustained and localized
release of 0.2 lg/day FAc implant resulted in
improved visual and anatomical outcomes
that were maintained for up to 36 months
[16]. However, the proportion of patients with
chronic DMO that achieved driving vision
following 0.2 lg/day FAc implant was reduced
in patients with lower baseline VA,
highlighting the importance of early
treatment for optimal visual outcomes [21].
Consequently, in patients with bilateral DME,
treatment of both eyes with 0.2 lg/day FAc
implant may be beneficial and, as it is not
contraindicated, should be considered.
Limitations
The main study limitations relate to the
retrospective nature of the study and the
limited study size (6 patients/12 eyes);
however, the current case series does provide a
real-world clinical perspective following the
bilateral administration of the 0.2 lg/day FAc
implant. Another limitation relates to the
period of follow-up and highlights the need
for further, larger prospective studies to assess
the efficacy and safety of the 0.2 lg/day FAc
implant in real-life practice as well as the
affecting of the outcomes of visual acuity.
Although baseline data were captured for the
patients included in this study, the full scope of
their disease history, including the timescale of
DME progression, which might impact on
response to 0.2 lg/day FAc implant, was not
captured. In addition, VA scores in these
patients were originally obtained using Snellen
charts and converted to approximate ETDRS
letter scores for the purposes of this analysis.
The line assignment method used in Snellen
charts (e.g., variable letter sizes and variable
letters per line, arbitrary progression of letter
size) can introduce a degree of variability in VA
scores, particularly in patients with poor VA
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[22]. As such, changes in VA should be
interpreted with a degree of caution.
CONCLUSION
This study demonstrates the potential efficacy of
0.2 lg/day FAc implant in both eyes of patients
with bilateral DME.CRTwas consistently reduced
in all but two eyes, which had relatively low CRT
values and good VA at baseline, and four eyes
maintained or achieved driving-level vision.
There was no notable increase in IOP and no
additional IOP-lowering treatment required
following 0.2 lg/day FAc implant; no other
treatment-related complications were reported.
These data suggest that it is safe to carry out
bilateral 0.2 lg/day FAc implant in patients with
DME in both eyes, with potential improvements
in DME and in the management of the long-term
negative impact of DME-mediated vision loss.
This is the first case series that the authors are
awareof, todemonstrate the feasibility of bilateral
0.2 lg/day FAc implant in a real-world setting,
and it suggests that, inpatientswithbilateralDME
insufficiently responsive to alternative therapies,
bilateral 0.2 lg/day FAc implant should be
considered.
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